secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2022-12-19T23:59:59+00:00
Accession:  0001193125-22-308316
Event type: other
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aeglea amends bylaws for universal proxy rules, DGCL changes, and meeting procedures
--------------------------------------------------------------------------------

- Board adopted amended bylaws effective December 15, 2022.
- Revised advance notice provisions: requires additional disclosures, limits nominees to directors up for election, and mandates nominee interviews.
- Added compliance measures for SEC Rule 14a-19 universal proxy, including certification and notice requirements.
- Updated adjournment procedures and stockholder meeting conduct; added emergency bylaw for quorum failure.
- Conformed notice provisions to DGCL electronic transmission amendments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000119312522308316/0001193125-22-308316-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000119312522308316/d414065d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-308316

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer